Delphine Imbert - Chinook Therapeutics VP Operations
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Insider
Delphine Imbert is VP Operations of Chinook Therapeutics
| Phone | 206 485 7241 |
| Web | https://www.chinooktx.com |
Chinook Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5685) %, meaning that it created substantial loss on money invested by shareholders. Chinook Therapeutics' management efficiency ratios could be used to measure how well Chinook Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Chinook Therapeutics currently holds 39.44 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Chinook Therapeutics has a current ratio of 12.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Chinook Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Vahe Bedian | Viridian Therapeutics | N/A | |
| Bhavesh Ashar | SpringWorks Therapeutics | 57 | |
| Marvin Caruthers | Viridian Therapeutics | 84 | |
| Jack Anders | Revolution Medicines | 47 | |
| Rami Elghandour | Arcellx | 45 | |
| John Nuss | Ventyx Biosciences | 65 | |
| Teresa McCarthy | Avidity Biosciences | 60 | |
| Jonathan MBA | Viridian Therapeutics | 49 | |
| MBA MBA | Vaxcyte | 63 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| MBA Perier | SpringWorks Therapeutics | 64 | |
| Peter Heerma | Travere Therapeutics | 52 | |
| Rik Derynck | Pliant Therapeutics | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Kate Aiken | Arcellx | N/A | |
| Ashish MBA | Vaxcyte | 52 | |
| Roger Bakale | Kura Oncology | N/A | |
| Todd IRC | Viridian Therapeutics | N/A | |
| MD MBA | Kalvista Pharmaceuticals | 51 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 |
Chinook Therapeutics Leadership Team
Elected by the shareholders, the Chinook Therapeutics' board of directors comprises two types of representatives: Chinook Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chinook. The board's role is to monitor Chinook Therapeutics' management team and ensure that shareholders' interests are well served. Chinook Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chinook Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tom Frohlich, Chief Officer | ||
| Jodi Jamieson, VP HR | ||
| MS MD, Sr Strategy | ||
| Eric MBA, Chief Officer | ||
| Kirk JD, Sr Counsel | ||
| Alan MD, Ex Officer | ||
| Andrew DVM, Chief Officer | ||
| Eric JD, CEO Pres | ||
| Noopur Liffick, VP Communications | ||
| Delphine Imbert, VP Operations |
Chinook Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chinook Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (39.98) % | |||
| Current Valuation | 2.64 B | |||
| Shares Outstanding | 67.05 M | |||
| Shares Owned By Insiders | 2.19 % | |||
| Shares Owned By Institutions | 96.71 % | |||
| Number Of Shares Shorted | 2.88 M | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 27.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stocks Directory Find actively traded stocks across global markets |